Literature DB >> 229941

Essential hypertension: effect of an oral inhibitor of angiotensin-converting enzyme.

G A MacGregor, N D Markandu, J E Roulston, J C Jones.   

Abstract

Captopril, a specific oral inhibitor of angiotensin-converting enzyme, was given to 18 unselected patients with moderate essential hypertension. Mean blood pressure fell by 14.5% at the maximum dose given, and this fall was significantly correlated with the initial plasma renin activity. The main fall in blood pressure occurred two hours after the first dose of captopril. These results suggest that captopril effectively lowers blood pressure in patients with essential hypertension and that the renin-angiotensin aldosterone system may maintain blood pressure in essential hypertension. This does not necessarily imply that the renin-angiotensin system is the cause of the high blood pressure.

Entities:  

Mesh:

Substances:

Year:  1979        PMID: 229941      PMCID: PMC1596971          DOI: 10.1136/bmj.2.6198.1106

Source DB:  PubMed          Journal:  Br Med J        ISSN: 0007-1447


  11 in total

1.  Clinical experience with use of ultrasound sphygmomanometer.

Authors:  C F George; P J Lewis; A Petrie
Journal:  Br Heart J       Date:  1975-08

2.  Antihypertensive effect of the oral angiotensin converting-enzyme inhibitor SQ 14225 in man.

Authors:  H Gavras; H R Brunner; G A Turini; G R Kershaw; C P Tifft; S Cuttelod; I Gavras; R A Vukovich; D N McKinstry
Journal:  N Engl J Med       Date:  1978-05-04       Impact factor: 91.245

3.  Agonist and antagonist effects of Sar1-ala8--angiotensin II in salt-loaded and salt-depleted normal man.

Authors:  G A MacGregor; P M Dawes
Journal:  Br J Clin Pharmacol       Date:  1976-06       Impact factor: 4.335

4.  Pressor response to 1-sar-8-ala-angiotensin II (saralasin) in hypertensive subjects.

Authors:  G H Anderson; D H Streeten; T G Dalakos
Journal:  Circ Res       Date:  1977-03       Impact factor: 17.367

5.  Measurement of plasma renin activity by radioimmunoassay after prolonged cold storage.

Authors:  J E Roulston; G A MacGregor
Journal:  Clin Chim Acta       Date:  1978-08-15       Impact factor: 3.786

6.  Converting enzyme inhibition with an orally active compound in hypertensive man.

Authors:  E L Bravo; R C Tarazi
Journal:  Hypertension       Date:  1979 Jan-Feb       Impact factor: 10.190

7.  Design of specific inhibitors of angiotensin-converting enzyme: new class of orally active antihypertensive agents.

Authors:  M A Ondetti; B Rubin; D W Cushman
Journal:  Science       Date:  1977-04-22       Impact factor: 47.728

8.  Accentuated vascular and endocrine response to SQ 20881 in hypertension.

Authors:  G H Williams; N K Hollenberg
Journal:  N Engl J Med       Date:  1977-07-28       Impact factor: 91.245

9.  Estimating renin participation in hypertension: superiority of converting enzyme inhibitor over saralasin.

Authors:  D B Case; J M Wallace; H J Keim; M A Weber; J I Drayer; R P White; J E Sealey; J H Laragh
Journal:  Am J Med       Date:  1976-11       Impact factor: 4.965

10.  A specific orally active inhibitor of angiotensin-converting enzyme in man.

Authors:  R K Ferguson; G A Turini; H R Brunner; H Gavras; D N McKinstry
Journal:  Lancet       Date:  1977-04-09       Impact factor: 79.321

View more
  17 in total

1.  Inhibitors of angiotensin I converting enzyme for treating hypertension.

Authors: 
Journal:  Br Med J       Date:  1980-09-06

2.  How adverse drug reactions can play a role in innovative drug research.

Authors:  F Rikken; R Vos
Journal:  Pharm World Sci       Date:  1995-11-24

Review 3.  ACE inhibitors for heart failure: a question of dose.

Authors:  J G Cleland; P A Poole-Wilson
Journal:  Br Heart J       Date:  1994-09

4.  Captopril in various forms of severe therapy-resistant hypertension.

Authors:  A Studer; T Lüscher; W Siegenthaler; W Vetter
Journal:  Klin Wochenschr       Date:  1981-01-15

5.  Haemodynamic profile of captopril treatment in various forms of hypertension.

Authors:  J H de Bruyn; A J Man in't Veld; G J Wenting; F H Derkx; M A Schalekamp
Journal:  Eur J Clin Pharmacol       Date:  1981       Impact factor: 2.953

6.  Captopril in Cushing's syndrome.

Authors:  P Greminger; W Vetter; H Groth; T Lüscher; W Tenschert; W Siegenthaler; H Vetter
Journal:  Klin Wochenschr       Date:  1984-09-17

7.  Dose finding studies with imidapril--a new ACE inhibitor.

Authors:  M J Vandenburg; E M Mackay; I Dews; T Pullan; S Brugier
Journal:  Br J Clin Pharmacol       Date:  1994-03       Impact factor: 4.335

8.  Minoxidil and captopril in severe hypertension.

Authors:  P Greminger; E Foerster; H Vetter; P Baumgart; W Vetter
Journal:  Klin Wochenschr       Date:  1986-04-01

9.  Relation of plasma renin activity to the antihypertensive effect of MK 421 in the rat.

Authors:  D Bradshaw; P H Franz; A L Sugden
Journal:  Br J Pharmacol       Date:  1982-05       Impact factor: 8.739

Review 10.  Captopril: a preliminary review of its pharmacological properties and therapeutic efficacy.

Authors:  R C Heel; R N Brogden; T M Speight; G S Avery
Journal:  Drugs       Date:  1980-12       Impact factor: 9.546

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.